Portopulmonary hypertension overview
|
Portopulmonary hypertension Microchapters |
|
Differentiating Portopulmonary hypertension from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Portopulmonary hypertension overview On the Web |
|
American Roentgen Ray Society Images of Portopulmonary hypertension overview |
|
Directions to Hospitals Treating Portopulmonary hypertension |
|
Risk calculators and risk factors for Portopulmonary hypertension overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Portopulmonary hypertension (PPH) is defined by the coexistence of portal and pulmonary hypertension. PPH is a serious complication of liver disease, present in 0.25 to 4% of all patients suffering from cirrhosis. Once an absolute contraindication to liver transplantation, it is no longer, thanks to rapid advances in the treatment of this condition.[1] Today, PPH is comorbid in 4-6% of those referred for a liver transplant.[2][3]
References
- ↑ Kuo PC et al. Portopulmonary Hypertension and the Liver Transplant Candidate. Transplantation 1999;67(8):1087-1093
- ↑ Torregosa et al. Role of Doppler echos in the assessment of portopulmonary hypertension in liver transplant candidates. Transplantation 2001;71:572-574
- ↑ Tapper EB, Knowles D, Heffron T, Lawrence EC, Csete M. Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition. Transplant Proc. 2009 Jun;41(5):1969-71.